Completed PHASE3 INTERVENTIONAL 2-arm NCT02040415

Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients

A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase Lll Clinical Trial to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients

Sponsor: Daewon Pharmaceutical Co., Ltd.

Conditions Acute Back Pain

Interventions DW-1030(eperisone HCl) 75mg Myonal Tab.(eperisone HCl) 50mg Placebo drug of DW-1030 Placebo drug of Myonal Tab.

Updated 5 times since 2017 Last updated: Oct 11, 2016 Started: Mar 31, 2014 Primary completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Back Pain, this trial is completed. The trial is conducted by Daewon Pharmaceutical Co., Ltd. and has accumulated 5 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daewon Pharmaceutical Co., Ltd.

Data source: Daewon Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.